<DOC>
	<DOCNO>NCT02978703</DOCNO>
	<brief_summary>Observational study evaluation clinical effectiveness daily clinical practice inhale combination propionic Fluticasone Salmeterol dose ( 500+50 ) mcg - Rolenium- administered Elpenhaler device approximately 2000 COPD ( Chronic Obstructive Pulmonary Disease ) patient FEV1 &lt; 50 % predict normal ( pre-bronchodilator ) , history repeat exacerbation significant symptom despite regular bronchodilator therapy Greece .</brief_summary>
	<brief_title>EvAluation Clinical Effectiveness Of RoLenium Administered With Elpenhaler Chronic Obstructive Pulmonary Disease ( COPD ) patientS Daily Clinical Practice , Greece</brief_title>
	<detailed_description>The scientific Objectives study Greek population real-life patient characteristic patient select treatment inhaled combination propionic Fluticasone Salmeterol ( 500+50 ) mcg - Rolenium- administered Elpenhaler device performance inhale combination term effectiveness safety approximately 2500 COPD ( Chronic Obstructive Pulmonary Disease ) patient FEV1 &lt; 50 % predict normal ( pre-bronchodilator ) , history repeat exacerbation significant symptom despite regular bronchodilator therapy treat Hospital outpatient specialist ward setting , daily clinical practice The primary endpoint study : • Change FEV1 , FVC , FEV1/FVC baseline 12 month ( ±2 week ) start take Rolenium® . The Secondary endpoint study : - Change lung function parameter baseline month 6 ( ±2 week ) start Rolenium® treatment - Incidence frequency exacerbation - Hospitalizations due COPD exacerbation - Change MRC Dyspnea index . - Patient 's satisfaction use Elpenhaler device assess FSI 10 Questionnaire 6 month 12 month ( ±2 week ) . - Concomitant administration inhale bronchodilator - ADRs treatment period ( via post-marketing procedure ) . Methodology The study purely observational , prospective study , collect data patient treat inhaled combination propionic Fluticasone Salmeterol ( 500+50 ) mcg , - administer Elpenhaler device Greece without interference treatment practice physicians involve data collection . Thus patient consider inclusion decision take treat inhaled combination propionic Fluticasone Salmeterol ( 500+50 ) mcg administer Elpenhaler device visit , diagnostic procedure monitor take place would happen patient include study . This mean data generate usual daily clinical practice collect study , extra examination study visit take place due study . The study comparative ; inhale combination propionic Fluticasone Salmeterol ( 500+50 ) mcg , - administer Elpenhaler device include . Consecutive patient start inhale combination propionic Fluticasone Salmeterol ( 500+50 ) mcg , - administer Elpenhaler device treatment shall inform study ask consent . Following usual practice patient follow 6 month 12 month ( ±2 week ) inhale treatment . The patient ' selection criterion accord SmPC .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>patient select treatment inhaled combination propionic Fluticasone Salmeterol ( 500+50 ) mcg Rolenium administer Elpenhaler device FEV1 &lt; 50 % predict normal ( prebronchodilator ) , history repeat exacerbation significant symptom despite regular bronchodilator therapy treat Hospital outpatient specialist ward setting , daily clinical practice sign informed consent compliant study procedures patient select treatment inhaled combination propionic FEV1 &gt; 50 % predict normal ( prebronchodilator ) , history repeat exacerbation sign informed consent compliant study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>